학술논문

Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment.
Document Type
Article
Source
Substance Abuse: Research & Treatment. 7/22/2022, p1-5. 5p.
Subject
*DISEASE relapse
*METHADONE treatment programs
*SUBSTANCE abuse
*BUPRENORPHINE
*CROSS-sectional method
*AGE distribution
*DOSE-effect relationship in pharmacology
*EMPLOYMENT
*MARITAL status
*METHADONE hydrochloride
*DRUG abusers
Language
ISSN
1178-2218
Abstract
Background: Lapse has been one of the major challenges in the treatment of drug dependence sometimes leading to its relapse. Objectives: The aim of this study was to determine the lapse rate in drug dependent patients as for the 2 methods of methadone maintenance treatment (MMT) and buprenorphine maintenance treatment (BMT) in Yazd city. Methods: In this cross-sectional study, 626 female and male patients who had referred to 5 SUD treatment centers in Yazd and had been treated with methadone and buprenorphine maintenance were studied. Participants were divided into 2 groups of MMT and BMT and were evaluated based on lapse within 6 months. Results: In this study, 60.9% of patients were treated with methadone but the rest were treated with buprenorphine. Overall, 33.1% of patients lapsed (35.2% for methadone and 29.8%for buprenorphine). Lapse in methadone treatment was correlated with age, occupational status, and duration of treatment (P <.05); it failed to correlated with any other demographic and clinical characteristics (P >.05). Lapse rate in buprenorphine treatment was also related to marital status and the drug used (P <.05). The mean dose of buprenorphine consumed showed no significant relationship with lapse (P >.05). The results demonstrated that given the low dose, lapse stood higher in the buprenorphine group than the methadone group; however, as to high dose, the buprenorphine group showed lower lapse than the other group. Conclusions: In regard with the high rate of lapse, it is recommended to consider the factors related to the 2 methods of treatments, and provide counseling and training programs to lower lapse in the patients. Ethics Committee (REC) approval code: IR.SSU.REC.1394.158. [ABSTRACT FROM AUTHOR]